---
title: 'Chimex, Emergent, SIGA, Merck & Kelun, Inceptor, Laekna, Kriya'
type: 'episode'
url: 'https://doc.social/episodes/chimex-emergent-siga-merck-kelun-inceptor-laekna-kriya'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2022-05-24'
audio: 'unavailable — the host retired the file'
---

# Chimex, Emergent, SIGA, Merck & Kelun, Inceptor, Laekna, Kriya

Pox progress, an oncology acquisition, and we look at $360M worth of biotech fundingFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesChimex, Emergent, SIGA Merck & KelunInceptor, Laekna, KriyaAbout the ShowLife Science…

## Summary

Pox progress, an oncology acquisition, and we look at $360M worth of biotech funding

**Find out more at
**[https://LifeScienceTodayPodcast.com
](https://lifesciencetodaypodcast.com/)
**Story References
**[Chimex, Emergent](https://www.biospace.com/article/releases/chimerix-announces-sale-of-tembexa-to-emergent-biosolutions-for-up-to-337-5-million-plus-royalties/?s=79), [SIGA](https://www.biospace.com/article/releases/siga-receives-approval-from-the-fda-for-intravenous-iv-formulation-of-tpoxx-tecovirimat-fda-approval-provides-an-important-option-for-those-unable-to-take-oral-formulation-of-tpoxx-/?s=74)
[Merck & Kelun
](https://pharmaphorum.com/news/merck-snaps-up-cancer-drug-from-chinas-kelun-in-1-4bn-deal/)[Inceptor](https://www.inceptor.bio/the-latest/inceptor-bio-announces-37-million-series-a-financing-to-develop-cell-therapies-for-difficult-to-treat-cancers), [Laekna](https://www.biospace.com/article/releases/laekna-therapeutics-raises-61-million-in-series-d-financing/?s=80), [Kriya**
**](https://www.biospace.com/article/kriya-therapeutics-scores-270-million-to-support-gene-therapy-development/)
**About the Show
**Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.